HeartBeam (NASDAQ: BEAT) is positioning itself to address the limitations of traditional 12-lead electrocardiogram (ECG) systems, which often involve cumbersome setups and restricted accessibility. The company is developing the HeartBeam System, described as the first cable-free, high-fidelity ECG system that captures the heart's electrical signals from three distinct directions and synthesizes them into a 12-lead ECG. This enables comprehensive arrhythmia assessment outside clinical settings.
According to a recent article, the HeartBeam System's design emphasizes user friendliness and portability. The device is the size of a credit card, making it easy for patients to use at home or on the go. Patients can capture their ECG by placing the device on their chest for 30 seconds, after which the data is transmitted securely to an on-call cardiologist for review. This streamlined process enables timely interventions when necessary.
The company's platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care—all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam holds 13 U.S. and 4 international-issued patents related to technology enablement.
For more information, visit HeartBeam.com. The full article can be viewed at nnw.fm/KrqTd.
Forward-looking statements in this article involve risks and uncertainties that may cause actual results to differ materially. These include factors set forth under "Risk Factors" in the Company's SEC filings, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Undue reliance should not be placed on forward-looking statements, and the company undertakes no duty to update them unless required by law.
